Energy Blocker Lonidamine Reverses Nimustine Resistance in Human Glioblastoma Cells through Energy Blockade, Redox Homeostasis Disruption, and O 6 -Methylguanine-DNA Methyltransferase Downregulation: In Vitro and In Vivo Validation.
Yaxing HuangPeng WangTengjiao FanNa ZhangLijiao ZhaoRugang ZhongGuohui SunPublished in: ACS pharmacology & translational science (2024)
Tumor resistance seriously hinders the clinical application of chloroethylnitrosoureas (CENUs), such as O 6 -methylguanine-DNA methylguanine (MGMT), which can repair O 6 -alkyl lesions, thereby inhibiting the formation of cytotoxic DNA interstrand cross-links (ICLs). Metabolic differences between tumor and normal cells provide a biochemical basis for novel therapeutic strategies aimed at selectively inhibiting tumor energy metabolism. In this study, the energy blocker lonidamine (LND) was selected as a chemo-sensitizer of nimustine (ACNU) to explore its potential effects and underlying mechanisms in human glioblastoma in vitro and in vivo . A series of cell-level studies showed that LND significantly increased the cytotoxic effects of ACNU on glioblastoma cells. Furthermore, LND plus ACNU enhanced the energy deficiency by inhibiting glycolysis and mitochondrial function. Notably, LND almost completely downregulated MGMT expression by inducing intracellular acidification. The number of lethal DNA ICLs produced by ACNU increased after the LND pretreatment. The combination of LND and ACNU aggravated cellular oxidative stress. In resistant SF763 mouse tumor xenografts, LND plus ACNU significantly inhibited tumor growth with fewer side effects than ACNU alone. Finally, we proposed a new "HMAGOMR" chemo-sensitizing mechanism through which LND may act as a potential chemo-sensitizer to reverse ACNU resistance in glioblastoma: moderate inhibition of hexokinase (HK) activity (H); mitochondrial dysfunction (M); suppressing adenosine triphosphate (ATP)-dependent drug efflux (A); changing redox homeostasis to inhibit GSH-mediated drug inactivation (G) and increasing intracellular oxidative stress (O); downregulating MGMT expression through intracellular acidification (M); and partial inhibition of energy-dependent DNA repair (R).
Keyphrases
- induced apoptosis
- signaling pathway
- oxidative stress
- circulating tumor
- cell cycle arrest
- dna repair
- single molecule
- cell free
- endothelial cells
- dna damage
- endoplasmic reticulum stress
- photodynamic therapy
- poor prognosis
- pi k akt
- reactive oxygen species
- cancer therapy
- cell death
- squamous cell carcinoma
- ischemia reperfusion injury
- locally advanced
- cell proliferation
- single cell
- radiation therapy
- cell therapy
- nucleic acid
- climate change
- induced pluripotent stem cells
- smoking cessation
- angiotensin ii
- human health
- drug delivery
- electronic health record
- fluorescent probe
- protein kinase